Next Article in Journal
Parental Attitudes and Perceptions of Support after Brief Clinician Intervention Predict Intentions to Accept the Adjuvanted Seasonal Influenza Vaccination: Findings from the Pediatric Influenza Vaccination Optimization Trial (PIVOT)–I
Previous Article in Journal
Clinicians Are Not Able to Infer Parental Intentions to Vaccinate Infants with a Seasonal Influenza Vaccine, and Perhaps They Should Not Try: Findings from the Pediatric Influenza Vaccination Optimization Trial (PIVOT)–IV
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 11
10.3390/vaccines10111956
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Seroprevalence of Varicella-Zoster Virus and Measles among Healthcare Workers in a Tertiary Medical Center in Korea

by
Ji Hyun Yun
1,
Eunsol Lee
2,
Jeong Hwa Choi
2,
Hyun Kyun Ki
1 and
Jiho Park
1,*
1
Division of Infectious Diseases, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, 120-1 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea
2
Department of Infection Control, Konkuk University Medical Center, Seoul 05029, Republic of Korea
*
Author to whom correspondence should be addressed.
Vaccines 2022, 10(11), 1956; https://doi.org/10.3390/vaccines10111956
Submission received: 21 October 2022 / Revised: 14 November 2022 / Accepted: 16 November 2022 / Published: 18 November 2022
Browse Figures
Versions Notes

Abstract

:
Measles and varicella still occur in the general population despite the widespread vaccination against them, and healthcare workers (HCWs) are still at risk of exposure to these diseases. Here, we evaluated the seroprevalence of measles and varicella-zoster virus (VZV) in HCWs and the trend of seroprevalence according to age, birth year, and occupational group. The serostatuses of measles and VZV of HCWs during new employee medical examinations between October 2015 and October 2021 were included. Thereafter, the trends of seroprevalence according to age, birth year, and occupational groups were evaluated. Overall, 2070 and 1827 HCWs were evaluated for VZV and measles serostatus, respectively. The seroprevalences of VZV and measles were 91% (1884/2070) and 70% (1284/1827), respectively. Younger HCWs had a significantly lower seroprevalence of measles (p = 0.02, age) and VZV (p = 0.003, birth year and p < 0.001, age). The seroprevalence of measles and VZV was significantly higher among doctors and nursing assistants than among nurses and other HCWs (p < 0.001 in both). In conclusion, the seroprevalence of measles and VZV significantly decreased in younger HCWs. Additionally, monitoring the serostatus of measles and VZV and the immunization of susceptible HCWs are required to prepare and control infectious diseases in healthcare facilities.

1. Introduction

Varicella and measles were major threats to public health because of their high transmission rates and complications [1,2]. The basic reproduction number of measles and varicella ranges from 13 to 18 and 3.7 to 5.0, respectively [3,4]. The incidence of varicella and measles decreased after the wide application of vaccination [5,6]. In Korea, varicella and measles vaccinations were included in the National Institutes of Health (NIH) program in 1985 and 2005, respectively. However, despite the efficacy of vaccination, varicella and measles still occur worldwide, including in countries with high vaccination rates [7,8,9,10]. Additionally, varicella and measles still occur in Korea, not only in childhood but also in adolescence and younger adults [11,12]. The primary failure of vaccines, secondary failures such as the waning effect of immunity, and the avoidance of vaccination could lead to a new outbreaks of these infectious diseases.
In a previous study that evaluated the seroprevalence of measles in Korea, the seroprevalence declined with time in the general adult population, particularly in those born between 1990 and 2001 [13]. The seroprevalence of measles in healthcare workers (HCWs) also reduced with time and was reported to be between 40% and 90% in HCWs who were born in the 1990s [14,15,16,17,18]. The waning effect of immunity might cause a decrease in the seroprevalence of measles [16]. With a decrease in the seroprevalence of measles, measles outbreaks among HCWs have been reported in some hospitals [19,20].
Seroprevalence of the varicella-zoster virus (VZV) was high and reached over 90% of the general adult population in Korea [21,22]. Recently, one study reported the seroprevalence of measles, mumps, rubella, and VZV in nurses in a tertiary hospital [15]. Although the seroprevalence of VZV is approximately 90% in all nurses, the seroprevalence of VZV significantly declined to 86% in young nurses. Previous studies that evaluated the seroprevalence of VZV in HCWs were limited by the small number of older age people and a limited population.
In this study, we evaluated the serostatuses of measles and VZV among HCWs, including doctors, nurses, nurse assistants, and other healthcare givers. The seroprevalence of measles and VZV and its trends were assessed according to birth year, age, and occupational groups.

2. Materials and Methods

2.1. Study Population

This study included HCWs who were examined for the serostatuses of measles and VZV during new employee medical checkups at Konkuk University Medical Center, a tertiary hospital in Korea, between October 2015 and October 2021. The seroprevalence of measles and VZV in HCWs was assessed according to their birth year, age, and occupational groups. Birth years were distributed in 5-year intervals; 1950–1954, 1955–1959, 1960–1964, 1965–1969, 1970–1974, 1974–1979, 1980–1984, 1984–1989, 1990–1994, and 1995–1999. Age groups were also distributed in 5-year intervals; 20–24, 25–29, 30–34, 35–39, 40–44, 45–49, 50–54, 55–59, and over 60. Age was calculated by the difference between the year of the test performed and the birth year. Additionally, the occupations of HCWs were grouped into doctors, nurses, nurse assistants, and other HCWs. The seroprevalence of VZV and measles was calculated as the seropositivity rate in each group. Thereafter, the changes in seroprevalence according to birth year and age groups and the comparison of seroprevalence between occupation groups were evaluated. The study was approved by the Institutional Review Board of the Konkuk University Medical Center (IRB No. 2022-08-069).

2.2. Changes in New Employee Medical Checkups

Recently hired HCWs were examined for their immunity to measles, VZV, hepatitis B, and hepatitis C, and the presence of latent tuberculosis as a new employee medical checkup. Only immunity to hepatitis B was assessed when the first hospital originally opened. The evaluations of immunity to VZV and measles were included in the new employee medical checkups in March 2009 and March 2016, respectively. The serostatus of measles was evaluated in HCWs who did not prove to have immunity to measles by providing a certificate of two-dose vaccination or previous infection. VZV serostatus was assessed to determine VZV immunity. Vaccinations for susceptible infectious diseases were recommended to HCWs who were susceptible to measles, VZV, and hepatitis B.

2.3. Evaluation of the Serostatus

The serostatus of measles was evaluated using a chemiluminescent immunoassay (LIAISON, DiaSorin, Italy). The test result was regarded as positive when the titer was equal to or above 16.5 AU/mL, negative when the titer was below 13.5 AU/mL, and indeterminate when the titer was between 13.5 and 16.5 AU/mL. The serostatus of VZV was evaluated by an enzyme-linked immunosorbent assay using a Chorus analyzer (DIESSE Diagnostica Senese, Siena, Italy). Additionally, the result was considered positive when the titer was above 1.2, negative when the titer was below 0.8, and indeterminate when the titer was between 0.8 and 1.2. The serostatuses of measles and VZV were examined according to the manufacturer’s instructions [23,24]. Positive antibody results were considered seropositive.

2.4. Statistical Analysis

The seroprevalence of VZV and measles was calculated among the overall population, birth year groups, age, and occupational groups. A correlation analysis was used to evaluate the correlation between the seroprevalence of VZV and measles according to birth year and age. Furthermore, a linear regression analysis was used to assess the trend of seroprevalence according to birth year and age. Comparison of the seroprevalence of measles and VZV between occupational groups was evaluated by Chi-square and Fisher’s exact tests. Moreover, comparisons of the seroprevalence between each occupational group were conducted. Statistical significance was considered when the p-value was < 0.05. In the comparison of seroprevalence between each occupation group (e.g., doctors vs. nurses), statistical significance was considered when the p-value was < 0.008 (according to Bonferroni’s method). Statistical analyses were conducted using SPSS (version 22.0; SPSS, Inc., Chicago, IL, USA), and graphs were obtained using PRISM-5 (GraphPad Software, San Diego, CA, USA).

3. Results

3.1. Study Population

In this study, overall, 2070 HCWs were examined for the serostatus of VZV, of which 1 (0.1%) person was born in 1950–1954, 4 (0.2%) in 1955–1959, 15 (0.7%) in 1960–1964, 29 (1.4%) in 1965–1969, 20 (1.0%) in 1970–1974, 28 (1.4%) in 1975–1979, 140 (6.8%) in 1980–1984, 350 (16.9%) in 1985–1989, 908 (43.9%) in 1990–1994, and 575 (27.8%) in 1995–1999. According to the age group, the population distribution was as follows: 699 (33.8%) in 20–24 years, 867 (41.9%) in 25–29 years, 309 (14.9%) in 30–34 years, 113 (5.5%) in 35–39 years, 17 (0.8%) in 40–44 years, 17 (0.8%) in 45–49 years, 29 (1.4%) in 50–54 years, 15 (0.7%) in 55–59 years, and 4 (0.2%) in over 60 years.
Overall, 1827 HCWs were assessed for the serostatus of measles, of which 1 (0.1%) was born in 1950–1954, 4 (0.2%) in 1955–1959, 15 (0.8%) in 1960–1964, 29 (1.6%) in 1965–1969, 19 (1.0%) in 1970–1974, 27 (1.5%) in 1975–1979, 134 (7.3%) in 1980–1984, 330 (18.1%) in 1985–1989, 836 (45.8%) in 1990–1994, and 432 (23.7%) in 1995–1999. According to the age group, population distribution was as follows: 573 (31.4%) in 20–24 years, 780 (42.7%) in 25–29 years, 288 (15.8%) in 30–34 years, 106 (5.8%) in 35–39 years, 16 (0.9%) in 40–44 years, 16 (0.9%) in 45–49 years, 29 (1.6%) in 50–54 years, 15 (0.8%) in 55–59 years, and 4 (0.2%) in over 60 years.

3.2. Seroprevalence of VZV

The seroprevalence of VZV was 91% (90–92%, 95% confidence interval [CI]), and the seroprevalence was 100% in HCWs who were born before 1965 (Table 1). In most birth year groups, seroprevalence was over 90%, except for 1995–1999 (89%). Additionally, seroprevalence was 100% in HCWs who were above 55 years old and lowest in HCWs who were less than 30 (90%) years old. HCWs with seronegative VZV were 87 (4%) and were only observed in HCWs who were born after the 1980s and were younger than those in their 40s.

3.3. Seroprevalence of Measles

The seroprevalence of measles was 70% (68–72%, 95% CI). The seroprevalence of the birth year groups was highest in 1950–1954 (100%) and lowest in 1975–1979 (63%) (Table 2). In most birth year groups, seroprevalence was lower than 90%, except for in 1950–1954 and 1965–1969 birth year groups. Moreover, seroprevalence was 100% in patients aged > 60 years and lowest in patients aged 20–24 (56%). In most age groups, seroprevalence was lower than 90%, except for the over 60 and 50–54 age groups. Seronegative HCWs were 296 (16%) and were only observed in HCWs who were born after the 1970s and were younger than those in their 50s.

3.4. Seroprevalence of Measles and VZV According to Occupational Group

The seroprevalence of VZV and measles was highest in nursing assistants (100% for VZV and 92% for measles) and lowest in nurses (91% for VZV and 68% for measles) and other HCWs (87% for VZV and 68% for measles) (Table 3). The occupational groups showed significant differences in the seroprevalence of measles and VZV (p < 0.001 in both). The seroprevalence of measles and VZV was significantly higher in doctors than in nurses (p = 0.002 for measles and p = 0.004 for VZV) or other HCWs (p = 0.005 for measles and p < 0.001 for VZV). Additionally, nurse assistants showed a higher seroprevalence of measles than nurses (p = 0.002) and other HCWs (p = 0.002). There were no significant differences between the seroprevalence of doctors and nurse assistants.

3.5. Trends of Seroprevalence of Varicella-Zoster and Measles

The seroprevalence of VZV significantly correlated with the birth year (p = 0.001) and age (p = 0.003). In the linear regression analysis, the seroprevalence of VZV significantly decreased in younger HCWs (p = 0.003, birth year and p < 0.001, age) (Figure 1). Furthermore, the seroprevalence of measles significantly correlated with age (p = 0.04) rather than birth year (p = 0.07), and the seroprevalence of measles was reduced in younger HCWs. This trend was significant in the age group (p = 0.02) rather than in the birth year group (p = 0.06) (Figure 2).

4. Discussion

In this study, the seroprevalence of VZV was 91%. Although the seroprevalence of VZV was above 90% in most age groups, the seroprevalence in the younger age group was lower than 90%. The seroprevalence of VZV significantly decreased with age. Moreover, the seroprevalence of measles was 70%, which was lower than 90% in most age groups. The seroprevalence of measles also significantly decreased with younger age. Doctors and nurse assistants had significantly higher seroprevalence than nurses and other HCWs.
The incidence of measles has decreased with measles vaccination [6]. However, nosocomial measles infections occur in many countries and threaten HCWs and patients, especially those who are immunocompromised [25]. In Korea, measles elimination was declared in 2006 with a two-dose measles vaccination, and the vaccination rate was >95% [26]. However, measles outbreaks have been reported in schools, healthcare facilities, and travelers to endemic countries [12]. Similar to measles, the incidence of varicella significantly decreases with vaccination [5,8]. In Korea, one dose of varicella vaccination was included in the NIH in 2005 [27]. Subsequently, the vaccination rate among elementary school entrance-aged children reached 93% in a study conducted in 2013 [28]. However, despite the high childhood vaccination rate, varicella incidence has been increasing [29]. Recently, the incidence of measles and varicella has decreased with the outbreak of coronavirus disease 2019 because of the social distancing [11,30]. In Korea, measles cases were 194 in 2019, six in 2020, and zero in 2021 and varicella cases were 82,868 in 2019, 31,430 in 2020, and 20,929 in 2021. However, as outbreak of coronavirus disease 2019 has decreased, social distancing has been reduced or halted in many countries. Because of concerns about the outbreak of transmissible infectious diseases, such as measles and VZV, after social distancing is halted, monitoring of immunity in HCWs and proper vaccination should be considered [31,32].
The present study showed 91% seropositivity for VZV among the HCWs. Our finding was similar to previous studies that reported a seroprevalence of over 90% in Korean adults [15,21,22,33]. The seroprevalence of VZV was higher than 90% in other countries, including Finland, Denmark, Japan, and Singapore [34,35,36,37]. These results could meet the population immunity threshold for varicella [38]. However, seroprevalence significantly decreased in younger HCWs in the present study, and this trend was also observed in another study conducted in Korea [15]. Furthermore, the seroprevalence of VZV in the younger population was lowered in Singapore [34]. When this trend was maintained, the seroprevalence of VZV decreased below the population immunity threshold. Conversely, this might have caused an improvement in the seroprevalence of VZV because the varicella vaccination in the NIH program was included in 2005. However, uncertainties still exist because breakthrough infections have been reported, especially in one dose-vaccinated population [9,39,40,41]. Therefore, continuous evaluation of the seroprevalence of VZV is required to determine the policies of healthcare facilities. Furthermore, a change in vaccination strategy from one dose to a two-dose vaccination should be considered to improve vaccine effectiveness.
The present study showed that the seroprevalence of measles was 70% and the seropositive rate was variable from 55% to 100% with age group. This variation in seropositive rate could result from the changes in vaccine strategy and the incidence of measles in Korea. Previous studies similarly reported the seroprevalence of measles from 73% to 93% among HCWs [14,15,16,17,18]. The seroprevalence of measles was lower than the threshold of population immunity and significantly lower in younger adults than in older adults, and this is one of the causes of the recent measles outbreaks in HCWs. In a meta-analysis conducted in Europe, the seroprevalence of measles decreased in HCWs born after 1980 [42]. Furthermore, studies conducted in Finland, Denmark, and Japan similarly reported a decline in the seroprevalence of measles in younger HCWs [35,36,37]. In Korea, measles vaccination was included in the NIH program in 1985, and a two-dose vaccination was initiated in 1995. In 2001, a catch-up vaccination was conducted for children born between 1986 and 1995 owing to the measles outbreak. Despite the two-dose vaccination of measles and the high vaccination rate, the seroprevalence of measles lowered at a younger age in HCWs. To enhance the immunity to measles, a third vaccination against measles might be needed. Some studies reported enhanced immunity for measles after the third vaccination [43,44,45]. Furthermore, seroconversion occurred in 99% of seronegative HCWs who received catch-up vaccination for measles [14]. However, more studies are needed to assess the adequate target, effectiveness, adverse effects of the third vaccination, and cost-effectiveness. The evaluation of measles immunity might still be helpful among HCWs because of the low seroprevalence of measles.
The seroprevalence of measles and VZV was significantly different between occupational groups. In previous studies, the seroprevalence of measles and VZV were significantly different between the occupational groups [14,46]. However, statistical significance was not observed when the multivariable analysis was conducted, including age, sex, occupation, and vaccination history. Because we could not evaluate the vaccination history of HCWs, an important factor of seroprevalence, the explanation could be limited. However, the mean ages of the doctors, nurses, nurse assistants, and other HCWs were 32, 25, 51, and 28, respectively, which were significantly different. Given that the present study showed the decline of seroprevalence of measles and VZV with younger age, relatively younger age of nurses and other HCWs than doctors and nurse assistants could have led to lower seroprevalence of those occupational groups.
The present study had some limitations. First, the effect of the NIH program on the seroprevalence of VZV among HCWs could not be evaluated. Therefore, continuous evaluation of seroprevalence among HCWs is required to assess the varicella vaccination effectiveness. Second, vaccination history was not evaluated. This study was conducted with new employee medical examinations; hence, we could not evaluate the vaccination history of HCWs. Considering that the vaccination rate of measles is >90% in the general population, measles vaccination history might have little effect on seroprevalence. Additionally, because we could not evaluate the varicella vaccination history, overestimation or underestimation of the seroprevalence of VZV could occur. However, the overall seroprevalence of VZV in this study was similar to that reported in previous studies. Third, because the present study was performed among HCWs, a selection bias could have influenced the results. Seroprevalence could be overestimated in HCWs compared with the general population. Fourth, the study was conducted at one medical center. Therefore, extrapolation to other geographical areas and healthcare facilities is limited. Fifth, the older age groups over the 50s were relatively small. Seroprevalence was evaluated during the new employee medical examination. Therefore, the older age groups were relatively smaller than the younger ones. However, the seroprevalence of measles and VZV significantly decreased in younger HCWs.

5. Conclusions

The seroprevalence of measles and VZV among the HCWs was 70% and 91%, respectively. The seroprevalence of measles and VZV was significantly lower in the younger HCWs than the older ones. Additionally, nurses and other HCWs had a lower seroprevalence of measles and VZV than doctors and nursing assistants. Continuous monitoring of seroprevalence is required to modify the infection control strategy and prevent outbreaks of infectious diseases in healthcare facilities.

Author Contributions

Conceptualization, J.H.Y. and E.L.; Data curation, E.L.; Formal analysis, J.H.Y.; Investigation, J.H.C.; Supervision, H.K.K.; Validation, J.P.; Writing—Original draft, J.H.Y.; Writing—Review and editing, J.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Lo Presti, C.; Curti, C.; Montana, M.; Bornet, C.; Vanelle, P. Chickenpox: An update. Med. Mal. Infect. 2019, 49, 1–8. [Google Scholar] [CrossRef] [PubMed]
  2. Hübschen, J.M.; Gouandjika-Vasilache, I.; Dina, J. Measles. Lancet 2022, 399, 678–690. [Google Scholar] [CrossRef]
  3. Guerra, F.M.; Bolotin, S.; Lim, G.; Heffernan, J.; Deeks, S.L.; Li, Y.; Crowcroft, N.S. The basic reproduction number (R0) of measles: A systematic review. Lancet Infect. Dis. 2017, 17, e420–e428. [Google Scholar] [CrossRef]
  4. Marangi, L.; Mirinaviciute, G.; Flem, E.; Scalia Tomba, G.; Guzzetta, G.; Freiesleben de Blasio, B.; Manfredi, P. The natural history of varicella zoster virus infection in Norway: Further insights on exogenous boosting and progressive immunity to herpes zoster. PLoS ONE 2017, 12, e0176845. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Baxter, R.; Ray, P.; Tran, T.N.; Black, S.; Shinefield, H.R.; Coplan, P.M.; Lewis, E.; Fireman, B.; Saddier, P. Long-term effectiveness of varicella vaccine: A 14-Year, prospective cohort study. Pediatrics 2013, 131, e1389–e1396. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Patel, M.K.; Goodson, J.L.; Alexander, J.P., Jr.; Kretsinger, K.; Sodha, S.V.; Steulet, C.; Gacic-Dobo, M.; Rota, P.A.; McFarland, J.; Menning, L.; et al. Progress toward regional measles elimination—Worldwide, 2000–2019. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1700–1705. [Google Scholar] [CrossRef]
  7. Hayman, D.T.S. Measles vaccination in an increasingly immunized and developed world. Hum. Vaccin. Immunother. 2019, 15, 28–33. [Google Scholar] [CrossRef] [Green Version]
  8. Varela, F.H.; Pinto, L.A.; Scotta, M.C. Global impact of varicella vaccination programs. Hum. Vaccin. Immunother. 2019, 15, 645–657. [Google Scholar] [CrossRef] [Green Version]
  9. Grose, C. Varicella vaccination of children in the United States: Assessment after the first decade 1995–2005. J. Clin. Virol. 2005, 33, 89–95; discussion 96–98. [Google Scholar] [CrossRef]
  10. Porter, A.; Goldfarb, J. Measles: A dangerous vaccine-preventable disease returns. Cleve. Clin. J. Med. 2019, 86, 393–398. [Google Scholar] [CrossRef]
  11. Kim, E.Y.; Jeong, S.Y.; Lee, G.H.; Song, J.; Lee, D.H. Characteristics of varicella outbreaks in Korea, 2018–2202. Public Health Wkly. Rep. 2021, 14, 652–663. [Google Scholar]
  12. Choi, S.; Cho, E.H. Analysis of the occurrence of measles in Korea, 2019. Public Health Wkly. Rep. 2020, 13, 2445–2458. [Google Scholar]
  13. Kang, H.J.; Han, Y.W.; Kim, S.J.; Kim, Y.J.; Kim, A.R.; Kim, J.A.; Jung, H.D.; Eom, H.E.; Park, O.; Kim, S.S. An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine 2017, 35, 4126–4132. [Google Scholar] [CrossRef] [PubMed]
  14. Han, S.B.; Park, S.H.; Yi, Y.; Ji, S.K.; Jang, S.H.; Park, M.H.; Lee, J.E.; Jeong, H.S.; Shin, S. Measles seroprevalence among healthcare workers in South Korea during the post-elimination period. Hum. Vaccin. Immunother. 2021, 17, 2517–2521. [Google Scholar] [CrossRef]
  15. Yoo, Y.; Park, W.J.; Cho, S.; Lim, D.Y.; Kim, S.; Kang, W.; Kim, H.; Moon, J.D. Seroprevalence of measles, mumps, rubella, and varicella-zoster antibodies in new female nurses in the Republic of Korea. Ann. Occup. Env. Med. 2021, 33, e19. [Google Scholar] [CrossRef]
  16. Jung, J.; Kim, S.K.; Kwak, S.H.; Hong, M.J.; Kim, S.H. Seroprevalence of Measles in Healthcare Workers in South Korea. Infect. Chemother. 2019, 51, 58–61. [Google Scholar] [CrossRef]
  17. Chang, H.H.; Kim, S.W.; Kwon, K.T.; Kim, H.I.; Kim, M.J.; Ryu, S.Y.; Kim, H.A.; Hur, J.; Kwon, H.H.; Hong, H.L. Preliminary report of seroprevalence of anti-measles immunoglobulin G among healthcare workers of 6 teaching hospitals of Daegu, Korea in 2019. Infect. Chemother. 2019, 51, 54–57. [Google Scholar] [CrossRef]
  18. Kwak, Y.G.; Song, J.E.; Oh, G.B.; Jeong, I.H.; Cho, C.R.; Kim, N.; Yoo, H.M.; Yoo, G.M.; Lee, M.J.; Kim, B.N. Comparison of the seroprevalence of measles antibodies among healthcare workers in two Korean hospitals in 2019. Infect. Chemother. 2020, 52, 93–97. [Google Scholar] [CrossRef] [Green Version]
  19. Song, K.; Lee, J.M.; Lee, E.J.; Lee, B.R.; Choi, J.Y.; Yun, J.; Lee, S.N.; Jang, M.Y.; Kim, H.W.; Kim, H.S.; et al. Control of a nosocomial measles outbreak among previously vaccinated adults in a population with high vaccine coverage: Korea, 2019. Eur. J. Clin. Microbiol. Infect. Dis. 2022, 41, 455–466. [Google Scholar] [CrossRef]
  20. Choe, Y.J.; Park, Y.J.; Kim, J.W.; Eom, H.E.; Park, O.; Oh, M.D.; Lee, J.K. An outbreak of measles in a university in Korea, 2014. J. Korean Med. Sci. 2017, 32, 1876–1878. [Google Scholar] [CrossRef]
  21. Lee, H.; Cho, H.K.; Kim, K.H. Seroepidemiology of varicella-zoster virus in Korea. J. Korean Med. Sci. 2013, 28, 195–199. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Choi, W.S.; Noh, J.Y.; Huh, J.Y.; Jo, Y.M.; Lee, J.; Song, J.Y.; Kim, W.J.; Cheong, H.J. Seroprevalence of varicella-zoster virus in Korea. J. Med. Virol. 2010, 82, 2123–2126. [Google Scholar] [CrossRef] [PubMed]
  23. Chris Maple, P.A.; Gunn, A.; Sellwood, J.; Brown, D.W.; Gray, J.J. Comparison of fifteen commercial assays for detecting Varicella Zoster virus IgG with reference to a time resolved fluorescence immunoassay (TRFIA) and the performance of two commercial assays for screening sera from immunocompromised individuals. J. Virol. Methods 2009, 155, 143–149. [Google Scholar] [CrossRef] [PubMed]
  24. de Ory, F.; Minguito, T.; Balfagon, P.; Sanz, J.C. Comparison of chemiluminescent immunoassay and ELISA for measles IgG and IgM. APMIS 2015, 123, 648–651. [Google Scholar] [CrossRef] [PubMed]
  25. Botelho-Nevers, E.; Gautret, P.; Biellik, R.; Brouqui, P. Nosocomial transmission of measles: An updated review. Vaccine 2012, 30, 3996–4001. [Google Scholar] [CrossRef] [PubMed]
  26. Lee, J.G. 2000~2001 result and lesson of the measles campaign for measles epidemic elimination. Korean J. Pediatr. Infect. Dis. 2001, 8, 280–284. [Google Scholar] [CrossRef]
  27. Infectious Diseases Homepage. Available online: https://www.kdca.go.kr/npt/biz/npp/portal/nppPblctDtaView.do?pblctDtaSeAt=8&pblctDtaSn=2039 (accessed on 20 October 2022).
  28. Choi, J.K.; Park, S.H.; Park, S.; Choi, S.M.; Kim, S.H.; Lee, D.G.; Yoo, J.H.; Choi, J.H.; Kang, J.H. Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003–2015. Hum. Vaccin. Immunother. 2019, 15, 2554–2560. [Google Scholar] [CrossRef]
  29. Lee, Y.H.; Choe, Y.J.; Cho, S.I.; Bang, J.H.; Oh, M.D.; Lee, J.K. Increasing varicella incidence rates among children in the Republic of Korea: An age-period-cohort analysis. Epidemiol. Infect. 2019, 147, e245. [Google Scholar] [CrossRef] [Green Version]
  30. Infectious Diseases Homepage. Available online: https://www.kdca.go.kr/npt/biz/npp/portal/nppPblctDtaView.do?pblctDtaSeAt=1&pblctDtaSn=2682 (accessed on 20 October 2022).
  31. Suzuki, A.; Nishiura, H. Transmission dynamics of varicella before, during and after the COVID-19 pandemic in Japan: A modelling study. Math. Biosci. Eng. 2022, 19, 5998–6012. [Google Scholar] [CrossRef]
  32. Thakur, M.; Zhou, R.; Mohan, M.; Marathe, A.; Chen, J.; Hoops, S.; Machi, D.; Lewis, B.; Vullikanti, A. COVID’s collateral damage: Likelihood of measles resurgence in the United States. BMC Infect. Dis. 2022, 22, 743. [Google Scholar] [CrossRef]
  33. Kang, J.H.; Park, Y.S.; Park, S.Y.; Kim, S.B.; Ko, K.P.; Seo, Y.H. Varicella seroprevalence among health care workers in Korea: Validity of self-reported history and cost-effectiveness of prevaccination screening. Am. J. Infect. Control 2014, 42, 885–887. [Google Scholar] [CrossRef] [PubMed]
  34. Fatha, N.; Ang, L.W.; Goh, K.T. Changing seroprevalence of varicella zoster virus infection in a tropical city state, Singapore. Int. J. Infect. Dis. 2014, 22, 73–77. [Google Scholar] [CrossRef] [PubMed]
  35. Kumakura, S.; Shibata, H.; Onoda, K.; Nishimura, N.; Matsuda, C.; Hirose, M. Seroprevalence survey on measles, mumps, rubella and varicella antibodies in healthcare workers in Japan: Sex, age, occupational-related differences and vaccine efficacy. Epidemiol. Infect. 2014, 142, 12–19. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Koivisto, K.; Puhakka, L.; Lappalainen, M.; Blomqvist, S.; Saxen, H.; Nieminen, T. Immunity against vaccine-preventable diseases in Finnish pediatric healthcare workers in 2015. Vaccine 2017, 35, 1608–1614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. von Linstow, M.L.; Yde Nielsen, A.; Kirkby, N.; Eltvedt, A.; Nordmann Winther, T.; Bybeck Nielsen, A.; Bang, D.; Poulsen, A. Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019. Eurosurveillance 2021, 26, 2001167. [Google Scholar] [CrossRef]
  38. Plans-Rubio, P. Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum. Vaccin. Immunother. 2012, 8, 184–188. [Google Scholar] [CrossRef] [Green Version]
  39. Kim, Y.; Hwang, J.Y.; Lee, K.M.; Lee, E.; Park, H. Cross-sectional study of varicella zoster virus immunity in healthy Korean children assessed by glycoprotein enzyme-linked immunosorbent assay and fluorescent antibody to membrane antigen test. Vaccines 2021, 9, 492. [Google Scholar] [CrossRef]
  40. Huang, W.C.; Huang, L.M.; Chang, I.S.; Tsai, F.Y.; Chang, L.Y. Varicella breakthrough infection and vaccine effectiveness in Taiwan. Vaccine 2011, 29, 2756–2760. [Google Scholar] [CrossRef]
  41. Pan, X.; Shu, M.; Ma, R.; Fang, T.; Dong, H.; Sun, Y.; Xu, G. Varicella breakthrough infection and effectiveness of 2-dose varicella vaccine in China. Vaccine 2018, 36, 5665–5670. [Google Scholar] [CrossRef]
  42. Bianchi, F.P.; Stefanizzi, P.; Trerotoli, P.; Tafuri, S. Sex and age as determinants of the seroprevalence of anti-measles IgG among European healthcare workers: A systematic review and meta-analysis. Vaccine 2022, 40, 3127–3141. [Google Scholar] [CrossRef]
  43. Kaaijk, P.; Nicolaie, M.A.; van Rooijen, D.; van Houten, M.A.; van der Klis, F.R.; Buisman, A.M.; van Binnendijk, R.S. Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose. Open Forum Infect. Dis. 2020, 7, ofaa505. [Google Scholar] [CrossRef] [PubMed]
  44. Quach, H.Q.; Chen, J.; Monroe, J.M.; Ratishvili, T.; Warner, N.D.; Grill, D.E.; Haralambieva, I.H.; Ovsyannikova, I.G.; Poland, G.A.; Kennedy, R.B. The influence of sex, BMI, and age on cellular and humoral immune responses against measles after a 3rd dose of MMR vaccine. J. Infect. Dis. 2022, jiac351. [Google Scholar] [CrossRef] [PubMed]
  45. Kaaijk, P.; Wijmenga-Monsuur, A.J.; Ten Hulscher, H.I.; Kerkhof, J.; Smits, G.; Nicolaie, M.A.; van Houten, M.A.; van Binnendijk, R.S. Antibody levels at 3-years follow-up of a third dose of measles-mumps-rubella vaccine in young adults. Vaccines 2022, 10, 132. [Google Scholar] [CrossRef] [PubMed]
  46. Gorny, A.W.; Mittal, C.; Saw, S.; Venkatachalam, I.; Fisher, D.A.; Tambyah, P.A. Varicella seroprevalence in healthcare workers in a tertiary hospital: An audit of cross-sectional data. BMC Res. Notes 2015, 8, 664. [Google Scholar] [CrossRef] [PubMed]
Vaccines 10 01956 g001 550
Figure 1. Changes of seroprevalence of varicella-zoster virus in healthcare workers according to birth year and age groups. The seroprevalence of varicella-zoster virus in healthcare workers significantly decreased according to (A) the birth year groups (p = 0.001) and (B) the age groups (p = 0.003).
Figure 1. Changes of seroprevalence of varicella-zoster virus in healthcare workers according to birth year and age groups. The seroprevalence of varicella-zoster virus in healthcare workers significantly decreased according to (A) the birth year groups (p = 0.001) and (B) the age groups (p = 0.003).
Vaccines 10 01956 g001
Vaccines 10 01956 g002 550
Figure 2. Changes of seroprevalence of measles in healthcare workers according to birth year and age groups. The seroprevalence of measles in healthcare workers decreased according to (A) the birth year groups (p = 0.07) and (B) significantly decreased according to the age groups (p = 0.04).
Figure 2. Changes of seroprevalence of measles in healthcare workers according to birth year and age groups. The seroprevalence of measles in healthcare workers decreased according to (A) the birth year groups (p = 0.07) and (B) significantly decreased according to the age groups (p = 0.04).
Vaccines 10 01956 g002
Table
Table 1. Immunologic status of the varicella-zoster virus of healthcare workers according to birth year and age group.
Table 1. Immunologic status of the varicella-zoster virus of healthcare workers according to birth year and age group.
TotalPositiveIndeterminateNegative
Birth year
1950–195411 (100)00
1955–195944 (100)00
1960–19641515 (100)00
1965–19692928 (97)1 (3)0
1970–19742018 (90)2 (10)0
1975–19792826 (93)2 (7)0
1980–1984140135 (96)1 (1)4 (3)
1985–1989350329 (94)10 (3)11 (3)
1990–1994908816 (90)49 (5)43 (5)
1995–1999575512 (89)34 (6)29 (5)
Age
>6044 (100)00
55–591515 (100)00
50–542928 (97)1 (3)0
45–491716 (94)1 (6)0
40–441716 (94)1 (6)0
35–39113108 (96)3 (3)2 (2)
30–34309291 (94)8 (3)10 (3)
25–29867780 (90)47 (5)40 (5)
20–24699626 (90)38 (5)35 (5)
Total20701884 (91)99 (5)87 (4)
Data are no. (%) of healthcare workers, unless otherwise indicated.
Table
Table 2. Immunologic status of measles of healthcare workers according to birth year and age group.
Table 2. Immunologic status of measles of healthcare workers according to birth year and age group.
TotalPositiveIndeterminateNegative
Birth year
1950–195411 (100)00
1955–195943 (75)1 (25)0
1960–19641512 (80)3 (20)0
1965–19692927 (93)2 (7)0
1970–19741914 (74)3 (16)2 (11)
1975–19792717 (63)7 (26)3 (11)
1980–198413489 (66)25 (19)20 (5)
1985–1989330268 (81)46 (14)16 (5)
1990–1994836537 (64)135 (16)164 (20)
1995–1999432316 (73)25 (6)91 (21)
Age
>6044 (100)00
55–591512 (80)3 (20)0
50–542926 (90)3 (10)0
45–491612 (75)2 (13)2 (13)
40–441611 (69)3 (19)2 (13)
35–3910682 (77)16 (15)8 (8)
30–34288234 (81)35 (12)19 (7)
25–29780583 (75)91 (12)106 (14)
20–24573320 (56)94 (16)159 (28)
Total18271284 (70)247 (14)296 (16)
Data are no. (%) of healthcare workers, unless otherwise indicated.
Table
Table 3. Seroprevalence of measles and varicella-zoster virus according to the occupational group.
Table 3. Seroprevalence of measles and varicella-zoster virus according to the occupational group.
Seroprevalence of Varicella-Zoster Virusp ValueSeroprevalence of Measlesp Value
Occupational group <0.001 <0.001
 Doctors449/473 (95) a,b 318/417 (76) a,b
 Nurses1013/1118 (91) a 641/943 (68) a,c
 Nursing assistants39/39 (100) 35/38 (92) c,d
 Other HCWs383/440 (87) b 290/429 (68) b,d
Data are presented seropositive no./total no. (%) of each occupational group. Abbreviations: HCW; healthcare workers. a Significantly different (p < 0.008) between doctors and nurses. b Significantly different (p < 0.008) between doctors and other HCWs. c Significantly different (p < 0.008) between nurses and nursing assistants. d Significantly different (p < 0.008) between nursing assistants and other HCWs.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Yun, J.H.; Lee, E.; Choi, J.H.; Ki, H.K.; Park, J. Seroprevalence of Varicella-Zoster Virus and Measles among Healthcare Workers in a Tertiary Medical Center in Korea. Vaccines 2022, 10, 1956. https://doi.org/10.3390/vaccines10111956

AMA Style

Yun JH, Lee E, Choi JH, Ki HK, Park J. Seroprevalence of Varicella-Zoster Virus and Measles among Healthcare Workers in a Tertiary Medical Center in Korea. Vaccines. 2022; 10(11):1956. https://doi.org/10.3390/vaccines10111956

Chicago/Turabian Style

Yun, Ji Hyun, Eunsol Lee, Jeong Hwa Choi, Hyun Kyun Ki, and Jiho Park. 2022. "Seroprevalence of Varicella-Zoster Virus and Measles among Healthcare Workers in a Tertiary Medical Center in Korea" Vaccines 10, no. 11: 1956. https://doi.org/10.3390/vaccines10111956

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop